The AMR Action Fund
Non-Profit & Charitable Organizations · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
JapanWebsite
www.amractionfund.comRevenue
<$5 MillionIndustry
About The AMR Action Fund
The AMR Action Fund Org Chart
Is The AMR Action Fund your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if The AMR Action Fund had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when The AMR Action Fund launches new products
Website visits: Recent activity has been detected on your website
The AMR Action Fund, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at The AMR Action Fund
Funding: Get notified immidiatlly once The AMR Action Fund has new funding data
Earning: See what the market has to say on The AMR Action Fund recently announced quarterly report
Check if The AMR Action Fund has recently received funding, and reach out quickly before it becomes old news!
Check out if The AMR Action Fund is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined The AMR Action Fund as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
The AMR Action Fund is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
The AMR Action Fund is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about The AMR Action Fund.
The AMR Action Fund Tech Stack
A closer look at the technologies used by The AMR Action Fund
Most Recent Scoops
The AMR Action Fund News & Media
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, announced today that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate. Antimicrobial resistance (AMR) is a growing public healthAMR Action Fund invests in first European antimicrobial company - Outsourcing-Pharma
AMR joins a Series C funding raise for BioVersys, which is developing antimicrobials against common drug-resistant bacteria that threaten public health.AMR Action Fund Announces Investment in BioVersys AG
Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing...AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and ...
/PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antibiotics, announced...
Top Non-Profit & Charitable Organizations Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs. They invest in biotechnology companies that are creating treatments for patients with life-threatening antimicrobial-resistant infections. The organization builds pa... Read More